Clinical

B-cell activating factor receptor chimeric antigen receptor (CAR) T-cell therapy caused cytotoxic effects on all chronic lymphocytic leukemia (CLL) cell lines.

Researchers investigate the expression of PARP1 in leukemias with BCR::ABL1 p190+ translocation, finding differential expression in ALL, AML, and CML but no significant correlation with clinical parameters.

Parth Rali, MD, Temple University Hospital, is looking forward to approaching pulmonary vascular diseases as a spectrum, especially when assessing pulmonary embolism and pulmonary hypertension, at CHEST 2024.

The researchers have detailed their complete findings of subcutaneous (SC) vs intravenous (IV) efgartigimod in generalized myasthenia gravis (gMG) from the phase 3 ADAPT-SC trial and initial findings from the open-label extension of the study, ADAPT-SC+.

Medical experts discuss the impact of third-line therapies (regorafenib, fruquintinib, FTD/TPI plus bevacizumab) on patient quality of life and share insights on patient adherence to these treatments.

Medical experts compare the toxicity profiles of FTD/TPI plus bevacizumab, regorafenib, and fruquintinib, and discuss practical strategies for managing treatment-related toxicities with these third-line therapies.

Panelists discuss how identifying type 2 inflammation in patients influences treatment decisions by steering clinicians toward targeted therapies, such as biologics or other immunomodulators, that specifically address the underlying inflammatory mechanisms rather than relying solely on symptomatic treatments.

Ajai Chari, MD, covered both recent FDA approvals and pipeline products, such as non-BCMA chimeric antigen receptor (CAR) T-cell therapies and trispecifics, during a symposium on Immunotherapy at the International Myeloma Society 21st Annual Meeting & Exposition.

Investigators from Florida Cancer Specialists & Research Institute explored questions surrounding minimal residual disease (MRD) negativity testing in an abstract presented at the International Myeloma Society 21st Annual Meeting & Exposition.

In less than a month, from August 20 to September 19, amivantamab (Ami; Rybrevant, Johnson & Johnson) received 2 approvals from the FDA for use in non–small cell lung cancer (NSCLC).

Panelists discuss how the selection between fam-trastuzumab deruxtecan-nxki and ado-trastuzumab emtansine is guided by findings from pivotal trials like DESTINY-Lung01 and DESTINY-Lung02, real-world patient outcomes compared with clinical trial results, and the management of common treatment-related adverse events associated with these HER2-directed therapies.

Panelists discuss how HER2-directed therapies in non–small cell lung cancer (NSCLC) are evolving, with experts examining the distinction between HER2 mutation and expression, evaluating the efficacy and safety of current treatments like trastuzumab deruxtecan and ado-trastuzumab emtansine, and considering their potential to reshape treatment approaches as recommended in NCCN guidelines.

A study found that opioid use, with or without benzodiazepines, significantly increases long-term mortality risk in patients with chronic obstructive pulmonary disease (COPD) over the age of 60 years.

September marked Ovarian Cancer Awareness Month, highlighting the importance of early detection and the need for equitable treatment access.

Key opinion leaders explore educational initiatives aimed at enhancing guideline adherence in cardiometabolic risk management, emphasizing effective tactics for improving health outcomes.

The expert panel analyzes strategies for overcoming barriers to prescribing first-line medications for cardiometabolic conditions.

Finerenone is at least as effective in patients who are in the hospital or were recently hospitalized for heart failure as those with stable condition, said Akshay Desai, MD, of Brigham & Women’s Hospital.

An oral session Friday at the International Myeloma Society 21st Annual Meeting & Exposition offered updates for the TRIMM-2 and RedirecTT-1 trials.

An adult patient with pulmonary arterial hypertension (PAH) and metastatic lung adenocarcinoma showed significant clinical improvement when chemotherapy and immunotherapy were added to PAH triple therapy.

The FDA approved dupilumab today as the first biologic treatment for patients with uncontrolled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype to significantly help reduce exacerbations and improve lung function.

Researchers report on the long-term immune changes in patients with refractory or relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax and rituximab plus bendamustine and rituximab.

While smoking is a key risk factor for chronic obstructive pulmonary disease (COPD), significant prevalence also exists among nonsmokers, highlighting the need for broader public health strategies.

NXP800 was granted orphan drug designation from the FDA in ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers.

The South Asian Healthcare Leadership Forum marked its 10th anniversary with a gathering of over 100 prominent physicians, policy makers, and executives at Brigham and Women’s Hospital.

A 3-year follow-up of patients with refractory/relapsed indolent non-Hodgkin (NHL) treated with a combination of magrolimab and rituximab showed no new treatment-emergent adverse events, suggesting long-term safety. The treatment also confirmed magrolimab penetration into the tumor.